DAFNA Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

DAFNA Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$255K	Sell	45,800 -5,200	-10%	-$39.6K	0.06%	81
2025 Q4	$375K	Buy	+51,000	New	+$312K	0.09%	72
2024 Q4	–	Sell	-12,845	Closed	-$160K	–	84
2024 Q3	$160K	Hold	12,845	–	–	0.04%	84
2024 Q2	$167K	Hold	12,845	–	–	0.04%	81
2024 Q1	$291K	Hold	12,845	–	–	0.07%	68
2023 Q4	$167K	Hold	12,845	–	–	0.04%	73
2023 Q3	$258K	Hold	12,845	–	–	0.08%	68
2023 Q2	$345K	Hold	12,845	–	–	0.09%	64
2023 Q1	$750K	Hold	12,845	–	–	0.22%	54
2022 Q4	$655K	Buy	+12,845	New	+$890K	0.18%	58

Other funds holding KPTI

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

DAFNA Capital Management's KPTI Position: Q1 2026 in Review

DAFNA Capital Management reduced its Karyopharm Therapeutics (KPTI) stake by 10% in Q1 2026, selling an estimated $39.6K and leaving 45,800 shares worth $255K. The position accounts for 0.06% of the portfolio, ranked #81.

DAFNA Capital Management first reported a position in KPTI in Q4 2022 and has held it in 10 quarters since. The position peaked at $750K in Q1 2023. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

DAFNA Capital Management held 45,800 shares of Karyopharm Therapeutics worth $255K as of Q1 2026.
DAFNA Capital Management sold 5,200 Karyopharm Therapeutics shares in Q1 2026, an estimated $39.6K.
Karyopharm Therapeutics made up 0.06% of DAFNA Capital Management's portfolio in Q1 2026, its #81 holding.
DAFNA Capital Management first reported a position in Karyopharm Therapeutics in Q4 2022 and has held it in 10 quarters since.
DAFNA Capital Management's Karyopharm Therapeutics position peaked at $750K in Q1 2023.
77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on DAFNA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.